Ischemic modified albumin (IMA) refers to the albumin whose N-terminal amino acid is modified (the binding site is occupied by copper ions or is acetylated or deleted) when tissue ischemia and reperfusion occurs. The characteristic is that the ability to bond with transition metals (nickel copper cobalt) is reduced. IMA is an early indicator of cell necrosis after myocardial ischemia, and its elevated level is also related to the severity of myocardial ischemia. Clinically, IMA is mainly used for early diagnosis of acute myocardial ischemia, and early diagnosis and risk stratification of acute coronary syndrome (ACS) (for reference only).